Definitive Contract HHSN261201600027C

<p>This is a $1,903,095.00 firm fixed price definitive contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Shuttle Pharmaceuticals, Inc. on September 9, 2019. The contract is for TOPIC 345: PREDICTIVE BIOMARKERS OF PROSTATE CANCER PATIENT SENSITIVITY FOR RADIATION LATE EFFECTS, with a period of performance through March 15, 2022. The contract does not have a set-aside designation.</p>

This is a $1,484,350.00 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Shuttle Pharmaceuticals, Inc., a small business Subchapter S Corporation. The contract is for cell-based models for prostate cancer health disparity research as part of the Cancer Moonshot program (Phase II). The contract has a total small business set aside designation and an ultimate completion date of November 16, 2021. This award builds upon a previous contract with...

<p>The National Cancer Institute (NCI) awarded a Small Business Innovation Research (SBIR) Program Phase I contract to Oncotherapeutica, Inc. for the development of a &quot;Prostate Cancer Selective Radioactive Prodrug&quot;. This $298,882 Firm Fixed Price contract was awarded on September 19, 2016 and has a completion date of November 18, 2017. The contract is designated as a Total Small Business set-aside.</p>

The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $354,415.00 Firm Fixed Price contract to Oncospace Inc., a Baltimore-based small business, to develop artificial intelligence (AI) tools to understand and duplicate expert radiation therapy planning for prostate cancer. This contract is part of the Small Business Innovation Research (SBIR) program and builds upon prior SBIR and National Science Foundation awards to Oncospace Inc....

<p>The National Cancer Institute (NCI), a civilian federal agency, awarded a $1,416,758.40 Cost Plus Fixed Fee contract to Sensopath Technologies, Inc., a Woman Owned Small Business, for a Small Business Innovation Research (SBIR) Program Phase II action. The contract, which has a total small business set aside, was awarded on September 28, 2012 with an ultimate completion date of May 22, 2015. The contract delivers research and development services under the SBIR program.</p>

<p>The National Cancer Institute (NCI) awarded a Small Business Innovation Research (SBIR) Program Phase I contract to Nanoscale Corporation for the development of a rapid in vitro screening assay to detect cancer biomarkers in urine and blood. The $150,000.00 firm-fixed-price contract has a completion date of May 2, 2013. This SBIR contract is part of the NCI's efforts to support small businesses in the development of innovative cancer-related technologies.</p>

The National Cancer Institute awarded a $455,000 firm fixed-price contract to Oncobiomix Inc., a small business located in San Antonio, Texas, under the Small Business Innovation Research (SBIR) Program Phase I. The award, issued on September 11, 2024, supports research and development of OnCobiomix, a microbiome-based diagnostic test designed to assess prostate cancer risk. As a Phase I SBIR award, this contract represents an initial feasibility and proof-of-concept stage, with a completion...

This is a Small Business Set-Aside contract awarded by the National Cancer Institute (NCI), a civilian agency, to DiaCarta L.L.C., a minority-owned, for-profit limited liability company. The $299,698.00 firm-fixed-price contract is for a Small Business Technology Transfer (STTR) Phase I research project to develop &quot;Predictive Biomarkers of Adverse Reactions to Radiation Treatment&quot; over a period from September 19, 2016 to June 18, 2017. The contract does not appear to be associated with...

The Department of Health and Human Services' National Institutes of Health National Cancer Institute awarded a Small Business Innovation Research (SBIR) Program Phase I contract to Pact &amp; Health LLC, a for-profit limited liability company located in Branford, Connecticut. The contract, awarded on September 11, 2019, has a potential value of $299,799.00 and is for the development of a versatile radiation-triggered phosphor platform for localized anti-cancer therapy. The contract is a...

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Detroit R&amp;D, Inc., a minority-owned, economically disadvantaged, woman-owned small business. The contract is for R&amp;D in biomedical basic research with a ceiling value of $299,097. The contract is a definitive, firm-fixed-price contract with a period of performance ending on September 21, 2016. This SBIR Phase I award will support the development of...